Variant in sex hormone-binding globulin gene and the risk of prostate cancer

Cancer Epidemiology Biomarkers and Prevention

Volumn 16, Issue 1, 2007, Pages 165-168

  Berndt, Sonja I ^a   Chatterjee, Nilanjan ^a   Huang, Wen Yi ^a   Chanock, Stephen J ^a   Welch, Robert ^a   Crawford, E David ^b   Hayes, Richard B ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOKETOREDUCTASE 1C3; CYTOCHROME P450 1A1; CYTOCHROME P450 1B1; CYTOCHROME P450 3A4; GONADORELIN; GONADORELIN 1; OXIDOREDUCTASE; PEPTIDES AND PROTEINS; PROTEIN ESR1; PROTEIN HSD173B; PROTEIN HSD3B2; PROTEIN SRD5A2; SEX HORMONE BINDING GLOBULIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER RISK; CANCER SCREENING; CASE CONTROL STUDY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA EXTRACTION; ETHNIC DIFFERENCE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HORMONAL REGULATION; HORMONE METABOLISM; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROSTATE CANCER; SINGLE NUCLEOTIDE POLYMORPHISM;

ANDROGEN-BINDING PROTEIN; CASE-CONTROL STUDIES; GENOTYPE; HUMANS; MALE; ODDS RATIO; POLYMORPHISM, GENETIC; PROSTATIC NEOPLASMS; RISK FACTORS; SEX HORMONE-BINDING GLOBULIN;

EID: 33846565998     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-06-0689     Document Type: Article

References (37)

1. Noble RL. The development of prostatic adenocarcinoma in Nb rats following prolonged sex hormone administration. Cancer Res 1977;37:1929-33.
2. Yuen MT, Leung LK, Wang J, Wong YC, Chan FL. Enhanced induction of prostatic dysplasia and carcinoma in Noble rat model by combination of neonatal estrogen exposure and hormonal treatments at adulthood. Int J Oncol 2005;27:1685-95.
3. Webber MM, Bello D, Quader S. Immortalized and tumorigenic adult human prostatic epithelial cell lines: characteristics and applications Part 2. Tumorigenic cell lines. Prostate 1997;30:58-64.
4. Pollard M, Luckert PH, Snyder D. Prevention and treatment of experimental prostate cancer in Lobund-Wistar rats. I. Effects of estradiol, dihydrotestosterone, and castration. Prostate 1989;15:95-103.
5. Daehlin L. On the effects of oestrogen in the male. Some effects of different oestrogenic substances in rats and men with prostatic carcinoma. Scand J Urol Nephrol Suppl 1985;91:1-44.
6. Kolesar JM, Goldspiel BR. Prostate cancer. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, editors. Pharmacotherapy: a pathophysiologic approach. Stamford (CT): Appleton & Lange; 1999. p. 2092-109.
7. Hsing AW, Reichardt JK, Stanczyk FZ. Hormones and prostate cancer: current perspectives and future directions. Prostate 2002;52:213-35.
8. Meikle AW, Bishop DT, Stringham JD, West DW. Quantitating genetic and nongenetic factors that determine plasma sex steroid variation in normal male twins. Metabolism 1987;35:1090-5.
9. Meikle AW, Stephenson RA, Lewis CM, Wiebke GA, Middleton RG. Age, genetic, and nongenetic factors influencing variation in serum sex steroids and zonal volumes of the prostate and benign prostatic hyperplasia in twins. Prostate 1997;33:105-11.
10. Ring HZ, Lessov CN, Reed T, et al. Heritability of plasma sex hormones and hormone binding globulin in adult male twins. J Clin Endocrinol Metab 2005;90:3653-8.
11. Makridakis N, Ross RK, Pike MC, et al. A prevalent missense substitution that modulates activity of prostatic steroid 5α-reductase. Cancer Res 1997;57:1020-2.
12. Hanna IH, Dawling S, Roodi N, Guengerich FP, Pari FF. Cytochrome P450 1B1 (CYP1B1) pharmacogenerics: association of polymorphisms with functional differences in estrogen hydroxylation activity. Cancer Res 2000;60:3440-4.
13. Kisselev P, Schunck WH, Roots I, Schwarz D. Association of CYP1A1 polymorphisms with differential metabolic activation of 17β-estradiol and estrone. Cancer Res 2005;65:2972-8.
14. Power SG, Bocchinfuso WP, Pallesen M, Warmels-Rodenhiser S, Van Baelen H, Hammond GL. Molecular analyses of a human sex hormone-binding globulin variant: evidence for an additional carbohydrate chain. J Clin Endocrinol Metab 1992;75:1066-70.
15. Ntais C, Polycarpou A, Tsatsoulis A. Molecular epidemiology of prostate cancer: androgens and polymorphisms in androgen-related genes. Eur J Endocrinol 2003;149:469~77.
16. Prorok PC, Andriole GL, Bresalier RS, et al. Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials 2000;21:273-309S.
17. Hayes RB, Sigurdson A, Moore L, et al. Methods for etiologic and early marker investigations in the PLCO trial. Mutat Res 2005;592:147-54.
18. Herrington DM, Howard TD, Brosnihan KB, et al. Common estrogen receptor polymorphism augments effects of hormone replacement therapy on E-selectin but not C-reactive protein. Circulation 2002;105:1879-82.
19. Hesselink DA, van Gelder T, van Schaik RH, et al. Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR-1, CYP3A4, and CYP3A5 genes. Clin Pharmacol Ther 2004;76:545-56.
20. Dunning AM, Dowsett M, Healey CS, et al. Polymorphisms associated with circulating sex hormone levels in postmenopausal women. J Natl Cancer Inst 2004;96:936-45.
21. Packer BR, Yeager M, Staats B, et al. SNP500Cancer: a public resource for sequence validation and assay development for genetic variation in candidate genes. Nucleic Acids Res 2004;32:D528-32.
22. Satagopan JM, Elston RC. Optimal two-stage genotyping in population-based association studies. Genet Epidemiol 2003;25:149-57.
23. Nakhla AM, Khan MS, Romas NP, Rosner W. Estradiol causes the rapid accumulation of cAMP in human prostate. Proc Natl Acad Sci U S A 1994;91:5402-5.
24. Nakhla AM, Khan MS, Rosner W. Biologically active steroids activate receptor-bound human sex hormone-binding globulin to cause LNCaP cells to accumulate adenosine 3′,5′-monophosphate. J Clin Endocrinol Metab 1990;71:398-404.
25. Hammes A, Andreassen TK, Spoelgen R, et al. Role of endocytosis in cellular uptake of sex steroids. Cell 2005;122:751-62.
26. Bocchinfuso WP, Ma KL, Lee WM, Warmels-Rodenhiser S, Hammond GL. Selective removal of glycosylation sites from sex hormone-binding globulin by site-directed mutagenesis. Endocrinology 1992;131:2331-6.
27. Petra PH, Griffin PR, Yates JR III, Moore K, Zhang W. Complete enzymatic deglycosylation of native sex steroid-binding protein (SBP or SHBG) of human and rabbit plasma: effect on the steroid-binding activity. Protein Sci 1992;1:902-9.
28. Sairam MR, Bhargavi GN. A role for glycosylation of the α subunit in transduction of biological signal in glycoprotein hormones. Science 1985;229:65-7.
29. Strel'chyonok OA, Avvakumov GV. Specific steroid-binding glycoproteins of human blood plasma: novel data on their structure and function. J Steroid Biochem 1990;35:519-34.
30. Ng KM, Catalano MG, Pinos T, et al. Evidence that fibulin family members contribute to the steroid-dependent extra-vascular sequestration of sex hormone-binding globulin. J Biol Chem 2006;281:15853-61.
31. Cousin P, Dechaud H, Grenot C, Lejeune H, Pugeat M. Human variant sex hormone-binding globulin (SHBG) with an additional carbohydrate chain has a reduced clearance rate in rabbit. J Clin Endocrinol Metab 1998;83:235-40.
32. Cousin P, Calemard-Michel L, Lejeune H, et al. Influence of SHBG gene pentanucleotide TAAAA repeat and D327N polymorphism on serum sex hormone-binding globulin concentration in hirsute women. J Clin Endocrinol Metab 2004;89:917-24.
33. Haiman CA, Riley SE, Freedman ML, Setiawan VW, Conti DV, Le Marchand L. Common genetic variation in the sex steroid hormone-binding globulin (SHBG) gene and circulating SHBG levels among postmenopausal women: the Multiethnic Cohort. J Clin Endocrinol Metab 2005;90:2198-204.
34. Gann PH, Hennekens CH, Ma J, Longcope C, Stampfer MJ. Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst 1996;88:1118-26.
35. Stattin P, Lumme S, Tenkanen L, et al. High levels of circulating testosterone are not associated with increased prostate cancer risk: a pooled prospective study. Int J Cancer 2004;108:418-24.
36. Hogeveen KN, Talikka M, Hammond GL. Human sex hormone-binding globulin promoter activity is influenced by a (TAAAA)n repeat element within an Alu sequence. J Biol Chem 2001;276:36383-90.
37. Xita N, Tsatsoulis A, Chatzikyriakidou A, Georgiou I. Association of the (TAAAA)n repeat polymorphism in the sex hormone-binding globulin (SHBG) gene with polycystic ovary syndrome and relation to SHBG serum levels. J Clin Endocrinol Metab 2003;88:5976-80.